Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GigCapital7 Corp. (GIGGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GIGGW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 464.52% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.04 - 0.17 | Updated Date 03/29/2025 |
52 Weeks Range 0.04 - 0.17 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
GigCapital7 Corp.
Company Overview
History and Background
GigCapital7 Corp. was a special purpose acquisition company (SPAC) formed in 2020. It aimed to complete a merger with a private operating company. GigCapital7 did merge with Iterum Therapeutics in 2021.
Core Business Areas
- Pharmaceuticals: Iterum Therapeutics focuses on developing and commercializing anti-infectives to combat multi-drug resistant pathogens.
Leadership and Structure
Iterum Therapeutics Inc. is led by a management team with experience in the pharmaceutical industry. The corporate structure includes a board of directors and various executive officers.
Top Products and Market Share
Key Offerings
- Sulopenem: Iterum Therapeutics' primary product is Sulopenem. It is an antibiotic intended to treat multi-drug resistant infections. Sulopenem has not received FDA approval. Competitors include existing broad-spectrum antibiotics from companies like Pfizer and Merck, as well as novel antibiotics developed by other pharmaceutical companies. Market share unavailable as Sulopenem is not yet approved.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the anti-infectives market, faces increasing demand due to rising antibiotic resistance. Developing new antibiotics is a costly and lengthy process.
Positioning
Iterum Therapeutics aims to address unmet needs in the treatment of multi-drug resistant infections, positioning itself in a niche market with potential for growth if Sulopenem gets approved.
Total Addressable Market (TAM)
The TAM for anti-infectives is substantial, estimated at billions of dollars. Iterum's success hinges on Sulopenem's market penetration and ability to capture a significant share of this TAM. Specific figures on market value currently unavailable.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical need (multi-drug resistant infections)
- Sulopenem's potential broad-spectrum activity
- Experienced management team in the pharmaceutical industry
Weaknesses
- Reliance on a single product (Sulopenem)
- Regulatory hurdles and FDA approval uncertainty
- Limited financial resources
Opportunities
- Potential FDA approval and market launch of Sulopenem
- Expansion into new geographical markets
- Partnerships with larger pharmaceutical companies
Threats
- Competition from existing and new antibiotics
- Unfavorable clinical trial results
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- PFE
- MRK
- RDHL
- ABBV
Competitive Landscape
Iterum Therapeutics faces intense competition from established pharmaceutical giants with extensive resources and approved antibiotic products. Its competitive advantage hinges on the potential superiority of Sulopenem. Iterum is currently at a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been negative, as the company has no approved product and is burning cash. Future growth depended on Sulopenem's approval but has been delayed.
Future Projections: Future projections depend on Sulopenem regulatory progress, if any.
Recent Initiatives: Focusing on re-analyzing trial data and resubmitting to the FDA (if they choose to go that route).
Summary
Iterum Therapeutics, formerly GigCapital7 Corp., faces significant challenges due to its reliance on Sulopenem, which has not received FDA approval. The company operates in a competitive market dominated by larger pharmaceutical companies. Financial performance is weak, and future prospects depend on regulatory success. There are now some additional hurdles as Iterum received a Complete Response Letter from the FDA for Sulopenem in July 2021.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions can change, and investment decisions should be made after consulting with a qualified professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GigCapital7 Corp.
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2024-09-11 | Chairman & CEO Dr. Avishay S. Katz Ph.D. | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.gigcapital7.com |
Full time employees - | Website https://www.gigcapital7.com | ||
GigCapital7 Corp. does not have significant operations. It focuses on effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus on companies in the technology, media, telecommunications, artificial intelligence and machine learning, cybersecurity, medical technology, medical equipment, and semiconductors and sustainable industries. The company was incorporated in 2024 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.